HLC urged Congress to preserve incentives for continued biopharmaceutical innovation while pursuing solutions that improve affordability for beneficiaries. The letter raised concerns about proposals to expand Medicare drug price negotiation and impose additional pricing controls, while supporting efforts to strengthen Medicare Part D market stability, expand access to Low-Income Subsidy benefits, and improve uptake of existing affordability programs.
To Congress
HLC response to Senate Finance Committee Democrats’ RFI on Drug Pricing
- Topics: Access, Competition, Innovation
Related Letters & Comments
HLC drives policy change through strategic letters, comments, and reports that promote private-sector innovation. Focused on priorities like Medicare reform, telehealth, and health equity, HLC engages with lawmakers and agencies to shape a smarter, more responsive healthcare system.
To Congress
Group letter urging House leadership to advance H.R. 2332/S.1101, the “SHARE Act”
HLC joined the Interstate Healthcare Collaborative and other healthcare organizations in urging House leadership to advance the bipartisan States Handling Access to Reciprocity for Employment (SHARE) Act (H.R. 2332/S. 1101). The legislation would ad…
To The Administration
Group letter to CMS opposing proposed remote monitoring restrictions in the 2027 Physician Fee Schedule
HLC also joined a coalition letter urging CMS not to finalize proposed changes to remote physiologic monitoring (RPM) and remote therapeutic monitoring (RTM) in the 2027 Physician Fee Schedule proposed rule that would restrict clinically integrated …
To Congress
Group letter to the Committee on Education and Workforce urging House passage of S. 2120, the Older Americans Act (OAA) Reauthorization Act
HLC joined the Healthy Aging Coalition in urging the House to pass S. 2120, the Older Americans Act Reauthorization Act, following its bipartisan passage in the Senate. The letter emphasizes the importance of aging-network services, including nutrit…
